PharmaFocus Today – Page 89 – media

New Cancer Detection Method as Quick and Easy as Blood Test

Researchers have unveiled a groundbreaking method to detect cancer, potentially simplifying the process to just taking a blood test. This technique, which boasts a 98.7% accuracy rate, combines optical imaging technology with fluorescent imaging. The method’s capability to identify cancer at its initial stages could significantly enhance the effectiveness of treatments. The highly accurate method developed by a research team at the University of Houston (Houston, TX, USA) enables the examination of extracellular vesicles or EVs—nanometer-sized membrane sacs present in the bloodstream that can transport various cargoes, including proteins, nucleic acids, and metabolites. In 2020, the research team introduced PANAROMA, an optical imaging technology featuring a glass slide covered with gold nanodiscs. This setup permits the observation of light transmission changes and the determination of nanoparticles as small as 25 nanometers in diameter. The technology’s name, PANORAMA, stands for Plasmonic Nano-aperture Label-free Imaging, highlighting its critical features. For this particular ...
- Source: drugdu
- 80
- June 6, 2024
POC STI Test Shortens Time from ED Arrival to Test Results

In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics to treat these STIs. This misuse has contributed to the development of antimicrobial-resistant strains of Neisseria gonorrhoeae (NG), prompting WHO to issue new guidelines for diagnosing STIs, including the use of point-of-care (POC) tests, focusing particularly on reducing antimicrobial resistance. The increasing STI rates have posed a significant challenge to hospital emergency departments, as traditional tests do not yield results quickly enough to guide treatment decisions during a patient’s visit. Consequently, clinicians often must decide on treatment before obtaining definitive results, exacerbating the issue of antibiotic resistance. Now, a new study has demonstrated that a POC polymerase chain reaction (PCR) test can reduce the time from specimen collection to STI result to just 47 minutes per patient, compared to the ...
- Source: drugdu
- 121
- June 6, 2024
FDA fast tracks Quince Therapeutics’ rare ataxia drug EryDex

California-based biotech Quince Therapeutics has won fast track designation from the US Food and Drug Administration (FDA) for its ataxia-telangiectasia (A-T) drug EryDex. According to the 3 June announcement, fast track designation was awarded to address a high unmet medical need for patients with A-T. The status allows for earlier interactions with the FDA as Quince seeks accelerated approval, and also the possibility to undergo rolling reviews. A-T is a rare disease of the nervous and immune systems, affecting motor movement and speech. EryDex utilises autologous intracellular drug encapsulation (AIDE) technology to administer dexamethasone sodium phosphate (DSP) into a patient’s red blood cells. Red blood cells filled with DSP are then reinfused into the patient, allowing for the slow release of steroids over several weeks, without the long-term toxicity commonly associated with chronic administration. The FDA lifted a partial clinical hold that was on the drug in October 2023, advancing ...
- Source: drugdu
- 71
- June 6, 2024
Weiguang Bio’s Human Plasminogen Complex Officially Approved

On May 21st, Weiguang Biological officially obtained the Certificate of Drug Registration of Human Plasminogen Complex approved by the State Drug Administration, adding one new product to its product pipeline! Up to now, Weiguang Bio has 11 products in three categories of blood products, and the comprehensive plasma utilization rate ranks the leading level in the industry. Prothrombin Complex Concentrate (PCC) approved by Weiguang is a concentrated preparation rich in coagulation factors II, VII, IX and X made from healthy human plasma, separated and purified by gel adsorption, ultrafiltration and other advanced technologies, and lyophilized by S/D and dry heat viral inactivation process. The ratio of Factor II, Factor VII, Factor IX and Factor X in the finished product is 1:1:1:1, all of them are 300IU, which is one of the rare four-factor PCC in the industry, and the quality of the product is at the leading level in the ...
- Source: drugdu
- 96
- June 6, 2024
invoX Pharma’s FS222 delivers encouraging solid tumour treatment results

invoX Pharma Limited has presented updated findings from its phase 1 study of FS222, showcasing significant anti-tumour activity in patients with advanced solid tumours. The data, revealed at the 2024 American Society of Clinical Oncology Annual Meeting, highlights FS222’s potential as a ground-breaking treatment option. FS222, a CD137/PD-L1 bispecific antibody, is part of invoX’s innovative product pipeline. The phase 1 trial involved 100 subjects and aimed to establish the drug’s safety and maximum tolerated dose. The study also assessed FS222’s anti-tumour activity, pharmacokinetics, and pharmacodynamics. The treatment, administered every four weeks, led to increased T cell proliferation and CD8+ T cell infiltration within tumours. While treatment-related adverse events were dose-dependent, they remained manageable and reversible. Dr Elena Garralda, Director of Early Drug Development at Vall d’Hebron University Hospital, commented on the drug’s potential: “While there have been great advances in immuno-oncology research, existing treatments continue to face challenges with response ...
- Source: drugdu
- 62
- June 6, 2024
EpiEndo and AlveoliX achieve milestone in ulcerative colitis treatment

EpiEndo Pharmaceuticals, a clinical-stage biopharmaceutical company, and AlveoliX, an innovator in organ-on-chip technology, have announced significant advancements in their joint project, the EpicoliX Project, to develop a novel treatment for ulcerative colitis (UC). Supported by Eurostars, the Icelandic Technology Development Fund, and Innosuisse, the project has identified Enterothelin, a Barriolide compound, as a lead candidate for a first-in-class therapy. UC is a debilitating inflammatory bowel disease affecting a significant portion of the global population. The EpicoliX Project, which began in May 2021, leverages AlveoliX’s organ-on-chip technology and EpiEndo’s expertise in chronic inflammatory diseases to meet the urgent need for effective UC treatments. The project’s key achievements include the development of a new gut-on-chip model that simulates the colon epithelium of UC patients. This model has been crucial in screening EpiEndo’s drug libraries and selecting Enterothelin as the lead candidate. The compound has undergone extensive preclinical testing, including in vivo studies, ...
- Source: drugdu
- 63
- June 6, 2024
Molecular Profiling Improves Diagnosis for Children with High Risk Cancers

Cancer remains the leading cause of disease-related death among children in most developed nations, and approximately one-fourth of these patients are diagnosed with aggressive, high-risk, or relapsed cancers, facing a dismal five-year survival rate of under 30%. Diagnosing these conditions accurately can be challenging, and even survivors often endure lifelong side effects from the harsh treatments required for their recovery. Now, researchers have demonstrated that through precision medicine, not only can diagnoses be more accurate, but implementing precision-guided, targeted treatments earlier can also enhance the two-year progression-free survival rates for young cancer patients. The Zero Childhood Cancer National Precision Medicine Program (ZERO) (Randwick, Australia), initially aimed at children with high-risk cancers, now includes all young cancer patients in Australia. Since its inception in 2017, the program has enrolled over 1,600 children. ZERO’s inaugural clinical trial, which ran from 2017 to 2022, yielded insights into genetic predispositions to cancer by identifying ...
- Source: drugdu
- 90
- June 5, 2024
DNA Spit Test More Accurate At Identifying Future Prostate Cancer Risk

Currently, the prostate-specific antigen (PSA) test is widely used to identify men who are at an increased risk of prostate cancer based on factors like age and ethnicity, as well as those showing symptoms. Elevated PSA levels may indicate prostate cancer, prompting further investigations such as MRI scans, biopsies, and treatments. However, the PSA test often results in false positives—incorrectly indicating prostate cancer in three out of four instances. It also detects cancers that grow so slowly they are unlikely to pose a significant health threat, leading to potentially unnecessary medical procedures. Now, a saliva-based test that individuals can perform at home has proven better at predicting the risk of developing prostate cancer than the traditional blood test. Researchers from The Institute of Cancer Research (London, UK) and The Royal Marsden NHS Foundation Trust (London, UK) conducted a trial of this innovative DNA test that screens for genetic variants associated ...
- Source: drugdu
- 89
- June 5, 2024
Virtual Therapeutics, Akili Interactive Strike Definitive Merger Agreement Seeking to Improve Mental Health Through Immersive Video Games

Don Tracy, Associate Editor Under terms of the deal, Akili will become a wholly owned subsidiary of Virtual Therapeutics, with Akili shareholders receiving $0.4340 per share of common stock in cash.Virtual Therapeutics and Akili, Inc. announced that they have agreed to terms on a definitive merger agreement, aiming to establish a digital health company that creates engaging and immersive games to improve mental health. Under terms of the merger, Akili will now work as a wholly owned company of Virtual Therapeutics, Akili shareholders will receive $0.4340 per share of common stock in cash, representing a 4% premium to the closing stock price.1 “In today’s global mental health crisis, patients deserve access to clinically validated solutions that address their specific needs. We have been able to advance multiple solutions on our platform since founding Virtual Therapeutics, and we look forward to taking a significant step forward through this merger,” said Dan ...
- Source: drugdu
- 94
- June 5, 2024
At ASCO, AstraZeneca Adds Data Supporting Expanded Use of Its Drugs in Lung Cancer

AstraZeneca’s Tagrisso and Imfinzi helped patients live longer in separate pivotal clinical trials evaluating the drugs in two different types of lung cancer. The results will be presented Sunday during the annual meeting of the American Society of Clinical Oncology. By Frank VinluanAstraZeneca, which already has a strong presence in lung cancer, is poised to deepen its reach in the disease with clinical data that support expanding the use of two of its approved therapies in ways that clinicians say will change the standard of care for many patients. The data are set for presentation Sunday during the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. First up is the targeted therapy osimertinib, which is marketed under the brand name Tagrisso. The small molecule blocks mutated forms of the EGFR protein, which drives cancer growth. The drug is already approved for use as a first-line treatment ...
- Source: drugdu
- 93
- June 5, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.